109 related articles for article (PubMed ID: 20049926)
1. Treatment of hemophilia in developing countries: a journey of a thousand miles.
Gruppo RA
Pediatr Blood Cancer; 2010 Mar; 54(3):348-9. PubMed ID: 20049926
[No Abstract] [Full Text] [Related]
2. Haemophilia treatment: where to from here? Have the risks increased?
Faed J
N Z Med J; 2003 Aug; 116(1180):U559. PubMed ID: 14581981
[No Abstract] [Full Text] [Related]
3. Management of hemophilia with minimal factor replacement in developing countries: role of ancillary therapy.
Chandy M
Semin Thromb Hemost; 2005 Nov; 31(5):501-6. PubMed ID: 16276457
[TBL] [Abstract][Full Text] [Related]
4. Surgery for hemophilia in developing countries.
Mathews V; Viswabandya A; Baidya S; George B; Nair S; Chandy M; Srivastava A
Semin Thromb Hemost; 2005 Nov; 31(5):538-43. PubMed ID: 16276462
[TBL] [Abstract][Full Text] [Related]
5. Demographics of hemophilia in developing countries.
Evatt BL
Semin Thromb Hemost; 2005 Nov; 31(5):489-94. PubMed ID: 16276455
[TBL] [Abstract][Full Text] [Related]
6. Towards a partnership of care for patients with haemophilia.
Carnahan M
N Z Med J; 2003 Dec; 116(1187):U721. PubMed ID: 14752544
[No Abstract] [Full Text] [Related]
7. Factors of life.
Carlisle D
Nurs Times; 1997 Feb 5-11; 93(6):56-7. PubMed ID: 9095935
[No Abstract] [Full Text] [Related]
8. [Not Available].
Hamostaseologie; 2019 Jun; 39(2):223-224. PubMed ID: 31362325
[No Abstract] [Full Text] [Related]
9. [The use of coagulation factors in hemophilia treatment].
Berger K; Schramm W
Pharm Unserer Zeit; 2006; 35(1):66-73. PubMed ID: 16465868
[No Abstract] [Full Text] [Related]
10. Prophylaxis in the haemophilia population-optimizing therapy.
Carcao MD; Aledort LM;
Haemophilia; 2007 May; 13(3):227-32. PubMed ID: 17498070
[No Abstract] [Full Text] [Related]
11. Bypassing agent regimens and costs for prophylaxis in patients with inhibitors.
Gringeri A
Haemophilia; 2009 Nov; 15(6):1336-7. PubMed ID: 19558488
[No Abstract] [Full Text] [Related]
12. Products for clotting factor replacement in developing countries.
Kasper CK
Semin Thromb Hemost; 2005 Nov; 31(5):507-12. PubMed ID: 16276458
[TBL] [Abstract][Full Text] [Related]
13. Managing hemophilia: safer, more effective but expensive.
Golden WE; Wells C
J Ark Med Soc; 2004 Aug; 101(2):50-1. PubMed ID: 15318445
[No Abstract] [Full Text] [Related]
14. The use of animal pharmacokinetic data to evaluate human dosing.
Lee ML
Haemophilia; 2010 May; 16(3):508-9. PubMed ID: 19563482
[No Abstract] [Full Text] [Related]
15. Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.
Berger KC; Feldman BM; Wasserman J; Schramm W; Blanchette V; Fischer K;
Haematologica; 2016 Mar; 101(3):266-8. PubMed ID: 26928247
[No Abstract] [Full Text] [Related]
16. Home treatment for hemophilia.
Hasiba U; Gorenc TJ; Oskins PB; Spero JA; Lewis JH
Pa Med; 1974 Dec; 77(12):50-1. PubMed ID: 4462071
[No Abstract] [Full Text] [Related]
17. Use of donated clotting factors for surgeries on haemophilic patients in a resource-constrained country: a kind donor, good outcome, change of practice and future directions.
Poudyal BS; Shrestha GS; Tuladhar S; Gyawali B; Sedain G; Battajo R; Maskey P; Paudyal S; Regmi S; Rc DR; Kouides P
Haemophilia; 2016 Sep; 22(5):e453-5. PubMed ID: 27353411
[No Abstract] [Full Text] [Related]
18. Circulating immune complexes pre and post clotting factor infusion in hemophilia.
Gomperts ED; Jordan S; Berg D; Sakai R; Boylen L
Thromb Haemost; 1981 Dec; 46(4):694-8. PubMed ID: 6800050
[No Abstract] [Full Text] [Related]
19. Product delivery in the developing world: options, opportunities and threats.
Farrugia A
Haemophilia; 2004 Oct; 10 Suppl 4():77-82. PubMed ID: 15479376
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
Monahan PE; Aledort LM;
Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
